Analgesics
Antiandrogens
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lactoferrin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Quercetin
Remdesivir
Vitamins

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Ivermectin as a Potential Therapeutic Agent for COVID-19 – case studies

Wijaya et al., Cermin Dunia Kedokteran, 47:7
Dec 2020  
  Twitter
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Case report on 3 confirmed cases of COVID-19 with significant clinical and radiological improvement after a single dose of ivermectin.
Wijaya et al., 31 Dec 2020, peer-reviewed, 2 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Ivermectin as a Potential Therapeutic Agent for COVID-19 -case studies
Natalia Sisca Wijaya, Sidharta Salim
In December 2019, an outbreak of a novel coronavirus (SARS-CoV-2) started in Wuhan, China, and has since become a global threat to human health. To date, the worldwide response to the COVID-19 outbreak has been limited mainly to monitoring/containment. Several types of drug, as well as vaccination, are still under investigation and clinical trials worldwide. Recently, a study demonstrated ~5000-fold reduction in SARS-CoV-2 virus at 48h in cell culture after a single treatment of ivermectin. A clinical study at the University of Utah found that the administration of ivermectin during COVID-19 illness in hospitalized patients is associated with lower mortality and hospital length of stay. We report three confirmed cases of COVID-19 infection with significant improvement clinically and radiologically, with following treatment single dose of ivermectin
References
Cally, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-COV-2 in vitro, Science Direct, doi:10.1016/j.antiviral.2020.104787
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of 2019 novel coronavirus infection in China, N Engl J Med, doi:10.1101/2020.02.06.20020974v1
Guzzo, Furtek, Porras, Chen, Tipping et al., Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol
Jaroslaw, Gorovits, COVID-19 alert
Lundberg, Pinkham, Baer, Amaya, Narayanan et al., Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis virus replication, Antivir. Res
Patel, Desai, Grainger, Mehra, Usefulness of ivermectin in COVID-19 illness
Õmura, Crump, The life and times of ivermectin -a success story, Nat Rev Microbiol, doi:10.1038/nrmicro1048
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit